Genentech R&D (gRED)
Genentech was founded in 1976, becoming a member of the Roche Group in 2009.
Genentech is a leading biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Its transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.
The organisation's headquarters are located in South San Francisco, USA.
![[Logo] Genentech](https://assets.roche.com/f/176343/1216x684/c85f1aefdc/logo-inpage-genentech.jpg/m/320x180/filters:format(webp):quality(90)/){kind=logo}
:quality(90)/){kind=logo}
:quality(90)/){kind=logo}
![[Logo] Chugai](https://assets.roche.com/f/176343/800x450/01aad13a58/logo-teaser-chugai.jpg/m/320x180/filters:format(webp):quality(90)/){kind=logo}
![[Thumbnail] RocheAccelerator](https://assets.roche.com/f/176343/740x610/7ea295051e/roche-accelerator-thumbnail2.jpg/m/320x180/filters:format(webp):quality(90)/)
:quality(90)/){kind=logo}
:quality(90)/){kind=logo}